Latest Equity Raise News

PolarX has raised $5 million through a share placement to ramp up exploration at its Humboldt Range Gold Project in Nevada, complementing a major joint venture with Northern Star Resources in Alaska.

iTech Minerals has announced a $2 million equity raise, including a $1 million Share Purchase Plan offering shares at a 14.2% discount to fund key mineral exploration projects and working capital.

Verity Resources has successfully raised $3 million through a two-tranche placement to accelerate drilling and resource upgrades at its Monument Gold Project amid strong gold market conditions.

Pearl Gull Iron Limited has agreed to sell its Cockatoo Island Project for A$4.5 million in cash, a 4% equity stake in Crestlink Pty Ltd, and ongoing royalties, marking a strategic shift as it seeks new growth opportunities.

FMR Resources has raised $3.4 million through a strategic equity placement to accelerate exploration at its Southern Porphyry target in Chile, aiming to unlock significant copper and gold potential.

Austral Resources has finalized key agreements with Glencore, including tolling, loan, and offtake contracts, paving the way for its acquisition of the Rocklands copper project and expanding its footprint in Queensland.

Catalyst Metals Limited reported record FY2025 financial results driven by stable operations at the Plutonic Gold Belt and a buoyant gold price environment. The company plans to double annual gold production to 200koz through development of new mines and expanded exploration.

Decidr AI Industries Ltd has reported a dramatic turnaround with a $71.1 million profit for FY2025, driven by its strategic acquisition of Decidr.ai Pty Ltd. The company is now moving to acquire full ownership of Decidr.ai, signaling a bold push into AI software.

BPH Global Limited reported a strong 161.7% revenue increase to nearly $288,000 for FY25, driven by new seaweed operations in Indonesia, yet the company remains in the red with a $1.3 million net loss. The firm continues to raise capital and integrate acquisitions as it charts a path forward.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.

Elixinol Wellness Limited reported a 12.8% increase in revenue to $7.64 million for the half-year ended June 2025, yet its net loss widened by 12.2% to $3.09 million, reflecting higher marketing and restructuring expenses following recent acquisitions.

Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.